RJFSA
RPRX

Raymond James Financial Services Advisors’s Repros Therapeutics Inc. RPRX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-11,500
Closed -$212K – 1172
2013
Q2 		$212K Buy
+11,500
New +$203K 0.01% 1100

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Raymond James Financial Services Advisors's RPRX Position: Q3 2013 in Review

Raymond James Financial Services Advisors sold out of Repros Therapeutics Inc. (RPRX) in Q3 2013, closing a stake of 11,500 shares — an estimated $212K sold.

Raymond James Financial Services Advisors first reported a position in RPRX in Q2 2013 and held it in 1 quarter. The position peaked at $212K in Q2 2013. 92 funds tracked by Wall St. Rank hold RPRX as of Q3 2013.

  • Raymond James Financial Services Advisors reported no remaining Repros Therapeutics Inc. position as of Q3 2013 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 11,500 Repros Therapeutics Inc. shares in Q3 2013, an estimated $212K.
  • Raymond James Financial Services Advisors first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Repros Therapeutics Inc. position peaked at $212K in Q2 2013.
  • 92 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q3 2013.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2013, filed 21 Oct 2013.